This study is in progress, not accepting new patients
RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jacque Duncan
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Jacque Duncan
Retinitis pigmentosa (RP) affects about 1 in 3,500 people worldwide. Age-related macular degeneration (AMD) affects as many as 1 in 4 people by the age of 75 and is the leading cause of blindness in people over age 50 in the United States. Both RP and AMD have a hereditary basis, and currently, there is no cure for either of these types of hereditary retinal degeneration.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- Additional information on study locations near you may be found at AllerganClinicalTrials.com. For any study not on AllerganClinicalTrials.com, please contact IR-CTRegistration@Allergan.com for assistance.
- ID
- NCT02556736
- Phase
- Phase 1/2 Retinitis Pigmentosa Research Study
- Study Type
- Interventional
- Participants
- About 14 people participating
- Last Updated